Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Behind every facility expansion, technology investment, and quality milestone in the CDMO sector is a leadership team making deliberate choices about where to focus, how to grow, and when to take calculated risks.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
A video roundup of the week’s top industry news stories.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
Contract Pharma Stream offers a centralized destination where users can watch expert-led sessions anytime, anywhere
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
The campus will occupy an estimated 460,000 square feet over 79 acres.
October 12, 2026
By: Patrick Lavery
Editor’s Take: By expanding its footprint in Georgia, UCB will aim to strengthen its biologic medicine manufacturing capabilities.
UCB dedicated the future site of its United States biologics manufacturing campus in the Rowen innovation district, Gwinnett County, Ga. The campus, estimated at 460,000 square feet, will occupy 79 acres within the district.
This realizes a part of UCB’s planned U.S. expansion first announced in March 2026.
UCB says this will be one of the largest life sciences manufacturing investments in Georgia history. The company selected Georgia in part due to its already strong life sciences ecosystem.
In addition, according to UCB, Georgia boasts a highly skilled workforce, robust infrastructure, and top academic and research institution access.
Now, UCB will aim to strengthen its capacity for biologic medicine manufacturing in the United States.
“At UCB, our purpose is to create value for people living with severe diseases,” UCB CEO Jean-Christophe Tellier said. “That purpose guides the science we pursue, where we invest, and the choices we make for the long term. Our manufacturing investment in the United States reflects our long-term commitment to patients, strengthening our ability to serve them.”
Tellier added UCB has a dual purpose of contributing to scientific innovation, highly skilled jobs, and economic growth in Georgia. With this new campus, the company plans to generate approximately $5 billion in economic impact on a $2 billion investment. This includes creating approximately 330 highly skilled permanent jobs and supporting more than 1000 construction jobs.
Belgium-based UCB counts more than 2000 of its 9000-plus workforce in the U.S., following its establishment in Atlanta in 1993. Already more than 400 of those U.S. workers are based at UCB’s metro Atlanta U.S. headquarters.
At the dedication, UCB unveiled Emmanuel Janssen Circle, a commemorative stonework installation at the roundabout at the campus entrance. This is named for UCB’s founder and his family.
Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !